{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T16:47:58Z","timestamp":1784738878772,"version":"3.55.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,4]]},"DOI":"10.7759\/cureus.70807","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T07:55:52Z","timestamp":1728028552000},"source":"Crossref","is-referenced-by-count":3,"title":["Abortive and Prophylactic Therapies to Treat Migraine in Pregnancy: A Review"],"prefix":"10.7759","author":[{"given":"Mohammed O","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Sarmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton RB","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007, 68:343-9. 10.1212\/01.wnl.0000252808.97649.21","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-012-0424-y","article-title":"Migraine in women: the role of hormones and their impact on vascular diseases","volume":"13","author":"Sacco S","year":"2012","unstructured":"Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain. 2012, 13:177-89. 10.1007\/s10194-012-0424-y","journal-title":"J Headache Pain"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11142070","article-title":"Determination of the frequency of migraine attacks in pregnant women and the ways they cope with headaches: a cross-sectional study","volume":"11","author":"Kardes G","year":"2023","unstructured":"Kardes G, Hadimli A, Ergenoglu AM. Determination of the frequency of migraine attacks in pregnant women and the ways they cope with headaches: a cross-sectional study. Healthcare (Basel). 2023, 11:2070. 10.3390\/healthcare11142070","journal-title":"Healthcare (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35284","article-title":"Study of the mechanisms and therapeutic approaches of migraine in women and pregnancy: a literature review","volume":"15","author":"Barus J","year":"2023","unstructured":"Barus J, Sudharta H, Adriani D. Study of the mechanisms and therapeutic approaches of migraine in women and pregnancy: a literature review. Cureus. 2023, 15:e35284. 10.7759\/cureus.35284","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-03395-8_1","article-title":"Non-pharmacologic aspects of management: \u201cAsthma and Allergic and Immunologic Diseases During Pregnancy - A Guide to Management\u201d","author":"Brauer DL","year":"2019","unstructured":"Brauer DL, Woessner KM. Non-pharmacologic aspects of management: \u201cAsthma and Allergic and Immunologic Diseases During Pregnancy - A Guide to Management\u201d. Asthma, Allergic and Immunologic Diseases During Pregnancy: A Guide to Management. Namazy J, Schatz M (ed): Springer, Cham; 2019. 1-14. 10.1007\/978-3-030-03395-8_1"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10995-006-0102-2","article-title":"Ensuring the safe and effective use of medications during pregnancy: planning and prevention through preconception care","volume":"10","author":"Cragan JD","year":"2006","unstructured":"Cragan JD, Friedman JM, Holmes LB, Uhl K, Green NS, Riley L. Ensuring the safe and effective use of medications during pregnancy: planning and prevention through preconception care. Matern Child Health J. 2006, 10:S129-35. 10.1007\/s10995-006-0102-2","journal-title":"Matern Child Health J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.36346\/sarjnhc.2019.v01i01.002","article-title":"Effect of non-pharmacological interventions on sleep quality during pregnancy among primigravida","volume":"1","author":"Rashed AB","year":"2019","unstructured":"Rashed AB, Khalil AK, Abo Shereda HM. Effect of non-pharmacological interventions on sleep quality during pregnancy among primigravida. South Asian Research Journal of Nursing and Healthcare. 2019, 1:8-17. 10.36346\/sarjnhc.2019.v01i01.002","journal-title":"South Asian Research Journal of Nursing and Healthcare"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.32598\/hms.28.3.3378.2","article-title":"Investigating non-pharmacologic treatment methods in reducing anxiety in pregnant women of low-risk and high-risk groups: a systematic review","volume":"28","author":"Rahimi F","year":"2022","unstructured":"Rahimi F, Moenimehr M. Investigating non-pharmacologic treatment methods in reducing anxiety in pregnant women of low-risk and high-risk groups: a systematic review. Intern Med Today. 2022, 28:300-29. 10.32598\/hms.28.3.3378.2","journal-title":"Intern Med Today"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01869.x","article-title":"Maternal characteristics and migraine pharmacotherapy during pregnancy: cross-sectional analysis of data from a large cohort study","volume":"29","author":"Nezvalov\u00e1-Henriksen K","year":"2009","unstructured":"Nezvalov\u00e1-Henriksen K, Spigset O, Nordeng H. Maternal characteristics and migraine pharmacotherapy during pregnancy: cross-sectional analysis of data from a large cohort study. Cephalalgia. 2009, 29:1267-76. 10.1111\/j.1468-2982.2009.01869.x","journal-title":"Cephalalgia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2181157","article-title":"Safety of drugs used for the treatment of migraine during pregnancy: a narrative review","volume":"16","author":"Spiteri JA","year":"2023","unstructured":"Spiteri JA, Camilleri G, Piccinni C, Sultana J. Safety of drugs used for the treatment of migraine during pregnancy: a narrative review. Expert Rev Clin Pharmacol. 2023, 16:207-17. 10.1080\/17512433.2023.2181157","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207089","article-title":"Adverse pregnancy outcomes and migraine: what we know and what we can do","volume":"100","author":"VanderPluym JH","year":"2023","unstructured":"VanderPluym JH. Adverse pregnancy outcomes and migraine: what we know and what we can do. Neurology. 2023, 100:645-6. 10.1212\/WNL.0000000000207089","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2004.04.1479","article-title":"Migraine in special populations. Treatment strategies for children and adolescents, pregnant women, and the elderly","volume":"115","author":"Gladstone JP","year":"2004","unstructured":"Gladstone JP, Eross EJ, Dodick DW. Migraine in special populations. Treatment strategies for children and adolescents, pregnant women, and the elderly. Postgrad Med. 2004, 115:39-50. 10.3810\/pgm.2004.04.1479","journal-title":"Postgrad Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1191091","article-title":"The impact of exposure to tobacco smoking and maternal trauma in fetal life on risk of migraine","volume":"17","author":"Kobus M","year":"2023","unstructured":"Kobus M, Sitek A, Antoszewski B, Ro\u017cniecki JJ, Pe\u0142ka J, \u017b\u0105dzi\u0144ska E. The impact of exposure to tobacco smoking and maternal trauma in fetal life on risk of migraine. Front Neurosci. 2023, 17:1191091. 10.3389\/fnins.2023.1191091","journal-title":"Front Neurosci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01704.x","article-title":"Migraine is a risk factor for hypertensive disorders in pregnancy: a prospective cohort study","volume":"29","author":"Facchinetti F","year":"2009","unstructured":"Facchinetti F, Allais G, Nappi RE, et al.. Migraine is a risk factor for hypertensive disorders in pregnancy: a prospective cohort study. Cephalalgia. 2009, 29:286-92. 10.1111\/j.1468-2982.2008.01704.x","journal-title":"Cephalalgia"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b664","article-title":"Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study","volume":"338","author":"Bushnell CD","year":"2009","unstructured":"Bushnell CD, Jamison M, James AH. Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study. BMJ. 2009, 338:b664. 10.1136\/bmj.b664","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/14767050500260566","article-title":"Risk of preeclampsia in relation to maternal history of migraine headaches","volume":"18","author":"Adeney KL","year":"2005","unstructured":"Adeney KL, Williams MA, Miller RS, Frederick IO, Sorensen TK, Luthy DA. Risk of preeclampsia in relation to maternal history of migraine headaches. J Matern Fetal Neonatal Med. 2005, 18:167-72. 10.1080\/14767050500260566","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01961.x","article-title":"Trimester-specific blood pressure levels and hypertensive disorders among pregnant migraineurs","volume":"51","author":"Williams MA","year":"2011","unstructured":"Williams MA, Peterlin BL, Gelaye B, Enquobahrie DA, Miller RS, Aurora SK. Trimester-specific blood pressure levels and hypertensive disorders among pregnant migraineurs. Headache. 2011, 51:1468-82. 10.1111\/j.1526-4610.2011.01961.x","journal-title":"Headache"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(99)00462-7","article-title":"Pregnancy outcomes in healthy nulliparas who developed hypertension","volume":"95","author":"Hauth JC","year":"2000","unstructured":"Hauth JC, Ewell MG, Levine RJ, et al.. Pregnancy outcomes in healthy nulliparas who developed hypertension. Obstet Gynecol. 2000, 95:24-8. 10.1016\/S0029-7844(99)00462-7","journal-title":"Obstet Gynecol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36828","article-title":"Relation and treatment approach of migraine in pregnancy and breastfeeding","volume":"15","author":"Turankar T","year":"2023","unstructured":"Turankar T, Sorte A, Wanjari MB, Chakole S, Sawale S. Relation and treatment approach of migraine in pregnancy and breastfeeding. Cureus. 2023, 15:e36828. 10.7759\/cureus.36828","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2013.4914","article-title":"Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders","volume":"168","author":"Liew Z","year":"2014","unstructured":"Liew Z, Ritz B, Rebordosa C, Lee PC, Olsen J. Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders. JAMA Pediatr. 2014, 168:313-20. 10.1001\/jamapediatrics.2013.4914","journal-title":"JAMA Pediatr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyt183","article-title":"Prenatal paracetamol exposure and child neurodevelopment: a sibling-controlled cohort study","volume":"42","author":"Brandlistuen RE","year":"2013","unstructured":"Brandlistuen RE, Ystrom E, Nulman I, Koren G, Nordeng H. Prenatal paracetamol exposure and child neurodevelopment: a sibling-controlled cohort study. Int J Epidemiol. 2013, 42:1702-13. 10.1093\/ije\/dyt183","journal-title":"Int J Epidemiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1094435","article-title":"Potential adverse actions of prenatal exposure of acetaminophen to offspring","volume":"14","author":"Wu K","year":"2023","unstructured":"Wu K, Lu W, Yan X. Potential adverse actions of prenatal exposure of acetaminophen to offspring. Front Pharmacol. 2023, 14:1094435. 10.3389\/fphar.2023.1094435","journal-title":"Front Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab623","article-title":"Prenatal acetaminophen use in women with autoimmune disorders and adverse pregnancy and birth outcomes","volume":"61","author":"Killion JA","year":"2022","unstructured":"Killion JA, Chambers C, Smith CJ, Bandoli G. Prenatal acetaminophen use in women with autoimmune disorders and adverse pregnancy and birth outcomes. Rheumatology (Oxford). 2022, 61:1630-8. 10.1093\/rheumatology\/keab623","journal-title":"Rheumatology (Oxford)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.37897\/RJN.2022.2.1","article-title":"Migraine and pregnancy","volume":"21","author":"Dumitru AE","year":"2022","unstructured":"Dumitru AE, Gica N, Botezatu R, Peltecu G, Panaitescu AM. Migraine and pregnancy. Ro J Neurol. 2022, 21:99-102. 10.37897\/RJN.2022.2.1","journal-title":"Ro J Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108210","article-title":"Associations between acetaminophen use during pregnancy and ADHD symptoms measured at ages 7 and 11 years","volume":"9","author":"Thompson JM","year":"2014","unstructured":"Thompson JM, Waldie KE, Wall CR, Murphy R, Mitchell EA. Associations between acetaminophen use during pregnancy and ADHD symptoms measured at ages 7 and 11 years. PLoS One. 2014, 9:e108210. 10.1371\/journal.pone.0108210","journal-title":"PLoS One"},{"key":"ref26","unstructured":"Pharmacovigilance Risk Assessment Committee (PRAC). Minutes of the meeting on 5-8 May 2014. (2014). https.\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-5-8-may-2014_en.pdf."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2127-9","article-title":"Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women","volume":"72","author":"Amundsen S","year":"2016","unstructured":"Amundsen S, \u00d8vreb\u00f8 TG, Amble NM, Poole AC, Nordeng H. Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women. Eur J Clin Pharmacol. 2016, 72:1525-35. 10.1007\/s00228-016-2127-9","journal-title":"Eur J Clin Pharmacol"},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.1017\/S0317167100118943","article-title":"Canadian Headache Society Guideline: acute drug therapy for migraine headache","volume":"40","author":"Worthington I","year":"2013","unstructured":"Worthington I, Pringsheim T, Gawel MJ, et al.. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013, 40:S1-80.","journal-title":"Can J Neurol Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004183","article-title":"Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: a nationwide cohort study","volume":"20","author":"Choi EY","year":"2023","unstructured":"Choi EY, Jeong HE, Noh Y, et al.. Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: a nationwide cohort study. PLoS Med. 2023, 20:e1004183. 10.1371\/journal.pmed.1004183","journal-title":"PLoS Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00430.2022","article-title":"Nonsteroidal anti-inflammatory drugs and implications for the cyclooxygenase pathway in embryonic development","volume":"324","author":"Leathers TA","year":"2023","unstructured":"Leathers TA, Rogers CD. Nonsteroidal anti-inflammatory drugs and implications for the cyclooxygenase pathway in embryonic development. Am J Physiol Cell Physiol. 2023, 324:C532-9. 10.1152\/ajpcell.00430.2022","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-021-03222-w","article-title":"Maternal non-steroidal anti-inflammatory drug exposure during pregnancy and risk of miscarriage: a systematic review and meta-analysis","volume":"78","author":"Ying XH","year":"2022","unstructured":"Ying XH, Bao DN, Jiang HY, Shi YD. Maternal non-steroidal anti-inflammatory drug exposure during pregnancy and risk of miscarriage: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2022, 78:171-80. 10.1007\/s00228-021-03222-w","journal-title":"Eur J Clin Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121130","article-title":"Gestational NSAIDs distinctly reprogram cardiac injury in preeclamptic rats: roles of cyclooxygenase, apoptotic and autophagic trails","volume":"310","author":"Ali MA","year":"2022","unstructured":"Ali MA, Abdelhady SA, Yacout DM, Kandil LS, Elblehi SS, El-Mas MM. Gestational NSAIDs distinctly reprogram cardiac injury in preeclamptic rats: roles of cyclooxygenase, apoptotic and autophagic trails. Life Sci. 2022, 310:121130. 10.1016\/j.lfs.2022.121130","journal-title":"Life Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/bdr2.1944","article-title":"Periconceptional nonsteroidal anti-inflammatory drug use, folic acid intake, and the risk of spina bifida","volume":"113","author":"Esposito DB","year":"2021","unstructured":"Esposito DB, Parker SE, Mitchell AA, Tinker SC, Werler MM. Periconceptional nonsteroidal anti-inflammatory drug use, folic acid intake, and the risk of spina bifida. Birth Defects Res. 2021, 113:1257-66. 10.1002\/bdr2.1944","journal-title":"Birth Defects Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/uog.21997","article-title":"Safety of non-steroidal anti-inflammatory drugs in postpartum period in women with hypertensive disorders of pregnancy: systematic review and meta-analysis","volume":"56","author":"Bellos I","year":"2020","unstructured":"Bellos I, Pergialiotis V, Antsaklis A, Loutradis D, Daskalakis G. Safety of non-steroidal anti-inflammatory drugs in postpartum period in women with hypertensive disorders of pregnancy: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2020, 56:329-39. 10.1002\/uog.21997","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2174\/138920012800166607","article-title":"Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn","volume":"13","author":"Antonucci R","year":"2012","unstructured":"Antonucci R, Zaffanello M, Puxeddu E, Porcella A, Cuzzolin L, Pilloni MD, Fanos V. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012, 13:474-90. 10.2174\/138920012800166607","journal-title":"Curr Drug Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-408078-2.00002-0","article-title":"Analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and antigout medications","author":"Malm H","year":"2015","unstructured":"Malm H, Borisch C. Analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and antigout medications. Drugs During Pregnancy and Lactation. Elsevier, Amsterdam; 2015. 27-58. 10.1016\/B978-0-12-408078-2.00002-0"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318162c89b","article-title":"Triptans in pregnancy","volume":"30","author":"Soldin OP","year":"2008","unstructured":"Soldin OP, Dahlin J, O'Mara DM. Triptans in pregnancy. Ther Drug Monit. 2008, 30:5-9. 10.1097\/FTD.0b013e318162c89b","journal-title":"Ther Drug Monit"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/cga.12456","article-title":"Analysis of triptan use during pregnancy in Japan: a case series","volume":"62","author":"Yamaguchi Y","year":"2022","unstructured":"Yamaguchi Y, Yamada T, Goto M, et al.. Analysis of triptan use during pregnancy in Japan: a case series. Congenit Anom (Kyoto). 2022, 62:78-81. 10.1111\/cga.12456","journal-title":"Congenit Anom (Kyoto)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01619.x","article-title":"Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study","volume":"50","author":"Nezvalov\u00e1-Henriksen K","year":"2010","unstructured":"Nezvalov\u00e1-Henriksen K, Spigset O, Nordeng H. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study. Headache. 2010, 50:563-75. 10.1111\/j.1526-4610.2010.01619.x","journal-title":"Headache"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-013-9831-x","article-title":"Triptan safety during pregnancy: a Norwegian population registry study","volume":"28","author":"Nezvalov\u00e1-Henriksen K","year":"2013","unstructured":"Nezvalov\u00e1-Henriksen K, Spigset O, Nordeng H. Triptan safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol. 2013, 28:759-69. 10.1007\/s10654-013-9831-x","journal-title":"Eur J Epidemiol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/head.12500","article-title":"Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis","volume":"55","author":"Marchenko A","year":"2015","unstructured":"Marchenko A, Etwel F, Olutunfese O, Nickel C, Koren G, Nulman I. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. Headache. 2015, 55:490-501. 10.1111\/head.12500","journal-title":"Headache"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4658","article-title":"Use of existing electronic health care databases to evaluate medication safety in pregnancy: triptan exposure in pregnancy as a case study","volume":"27","author":"Yusuf A","year":"2018","unstructured":"Yusuf A, Chia V, Xue F, Mikol DD, Bollinger L, Cangialose C. Use of existing electronic health care databases to evaluate medication safety in pregnancy: triptan exposure in pregnancy as a case study. Pharmacoepidemiol Drug Saf. 2018, 27:1309-15. 10.1002\/pds.4658","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/ppe.12253","article-title":"Prenatal triptan exposure and internalising and externalising behaviour problems in 3-year-old children: results from the Norwegian Mother and Child Cohort Study","volume":"30","author":"Wood ME","year":"2016","unstructured":"Wood ME, Lapane K, Frazier JA, Ystrom E, Mick EO, Nordeng H. Prenatal triptan exposure and internalising and externalising behaviour problems in 3-year-old children: results from the Norwegian Mother and Child Cohort Study. Paediatr Perinat Epidemiol. 2016, 30:190-200. 10.1111\/ppe.12253","journal-title":"Paediatr Perinat Epidemiol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/TERA.1420270109","article-title":"Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations","volume":"27","author":"Michaelis J","year":"1983","unstructured":"Michaelis J, Michaelis H, Gl\u00fcck E., Koller S.. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. Teratology. 1983, 27:57-64. 10.1002\/TERA.1420270109","journal-title":"Teratology"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417724152","article-title":"Pregnancy outcome after anti-migraine triptan use: a prospective observational cohort study","volume":"38","author":"Spielmann K","year":"2018","unstructured":"Spielmann K, Kayser A, Beck E, Meister R, Schaefer C. Pregnancy outcome after anti-migraine triptan use: a prospective observational cohort study. Cephalalgia. 2018, 38:1081-92. 10.1177\/0333102417724152","journal-title":"Cephalalgia"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/OGX.0000000000001094","article-title":"Opioid use in pregnancy: a review","volume":"78","author":"Ryan KS","year":"2023","unstructured":"Ryan KS, Prewitt KC, Hayer S, Hedges MA, Benson AE, Lo JO. Opioid use in pregnancy: a review. Obstet Gynecol Surv. 2023, 78:35-49. 10.1097\/OGX.0000000000001094","journal-title":"Obstet Gynecol Surv"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.52504\/001c.16759","article-title":"The effects of opioids during pregnancy: a literature review","volume":"4","author":"Asdjodi S","year":"2020","unstructured":"Asdjodi S, Rubarth RB, Hardy J, Lee H. The effects of opioids during pregnancy: a literature review. Georgetown Med Rev. 2020, 4:1-12. 10.52504\/001c.16759","journal-title":"Georgetown Med Rev"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1556740","article-title":"Prescription opioids in pregnancy and birth outcomes: a review of the literature","volume":"4","author":"Yazdy MM","year":"2015","unstructured":"Yazdy MM, Desai RJ, Brogly SB. Prescription opioids in pregnancy and birth outcomes: a review of the literature. J Pediatr Genet. 2015, 4:56-70. 10.1055\/s-0035-1556740","journal-title":"J Pediatr Genet"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2022.0118","article-title":"Characteristics of individuals in the United States who used opioids during pregnancy","volume":"32","author":"Nguyen RH","year":"2023","unstructured":"Nguyen RH, Knapp EA, Li X, et al.. Characteristics of individuals in the United States who used opioids during pregnancy. J Womens Health (Larchmt). 2023, 32:161-70. 10.1089\/jwh.2022.0118","journal-title":"J Womens Health (Larchmt)"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4848","article-title":"Use of opioids during pregnancy and effects of pregnancy outcomes","volume":"28","author":"F\u00e4ltmarch S","year":"2019","unstructured":"F\u00e4ltmarch S, Perttil\u00e4 I, Tuomi U, et al.. Use of opioids during pregnancy and effects of pregnancy outcomes. Pharmacoepidemiol Drug Saf. 2019, 28:1239-45. 10.1002\/pds.4848","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13070492","article-title":"The usage of ergot (Claviceps purpurea (Fr.) Tul.) in obstetrics and gynecology: a historical perspective","volume":"13","author":"Smakosz A","year":"2021","unstructured":"Smakosz A, Kurzyna W, Rudko M, D\u0105sal M. The usage of ergot (Claviceps purpurea (Fr.) Tul.) in obstetrics and gynecology: a historical perspective. Toxins (Basel). 2021, 13:492. 10.3390\/toxins13070492","journal-title":"Toxins (Basel)"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/head.13434","article-title":"Migraine treatment in pregnant women presenting to acute care: a retrospective observational study","volume":"59","author":"Hamilton KT","year":"2019","unstructured":"Hamilton KT, Robbins MS. Migraine treatment in pregnant women presenting to acute care: a retrospective observational study. Headache. 2019, 59:173-9. 10.1111\/head.13434","journal-title":"Headache"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2005.46.6.866","article-title":"An autopsy case of postpartum acute myocardial infarction associated with postpartum ergot alkaloids administration in old-aged pregnant women","volume":"46","author":"Eom M","year":"2005","unstructured":"Eom M, Lee JH, Chung JH, Lee H. An autopsy case of postpartum acute myocardial infarction associated with postpartum ergot alkaloids administration in old-aged pregnant women. Yonsei Med J. 2005, 46:866-9. 10.3349\/ymj.2005.46.6.866","journal-title":"Yonsei Med J"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1969.tb107560.x","article-title":"Mesenteric vascular occlusion in pregnancy: suspected ergot poisoning","volume":"2","author":"Holmes G","year":"1969","unstructured":"Holmes G, Martin E, Tabua S. Mesenteric vascular occlusion in pregnancy: suspected ergot poisoning. Med J Aust. 1969, 2:1009-11. 10.5694\/j.1326-5377.1969.tb107560.x","journal-title":"Med J Aust"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/0890-6238(96)00063-9","article-title":"Pregnancy outcome after treatment with the ergot derivative, cabergoline","volume":"10","author":"Robert E","year":"1996","unstructured":"Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol. 1996, 10:333-7. 10.1016\/0890-6238(96)00063-9","journal-title":"Reprod Toxicol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-17898-7_23","article-title":"Maternal use of drugs for migraine and infant congenital malformations","author":"K\u00e4ll\u00e9n B","year":"2019","unstructured":"K\u00e4ll\u00e9n B. Maternal use of drugs for migraine and infant congenital malformations. Maternal Drug Use and Infant Congenital Malformations. Springer, Cham; 2019. 247-53. 10.1007\/978-3-030-17898-7_23"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-0002-8_6","article-title":"Treatment of pregnant and breastfeeding patients with acute headache in the ED","author":"Marcus DA","unstructured":"Marcus DA, Bain PA. Treatment of pregnant and breastfeeding patients with acute headache in the ED. Practical Assessment and Treatment of the Patient With Headaches in the Emergency Department and Urgent Care Clinic. 2012 (ed): Springer, New York; 133-54. 10.1007\/978-1-4614-0002-8_6"},{"key":"ref58","article-title":"Practical selection of antiemetics in the ambulatory setting","volume":"91","author":"Flake ZA","year":"2015","unstructured":"Flake ZA, Linn BS, Hornecker JR. Practical selection of antiemetics in the ambulatory setting. Am Fam Physician. 2015, 91:293-6.","journal-title":"Am Fam Physician"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-011-0150-9","article-title":"Use of dopamine antagonists in treatment of migraine","volume":"14","author":"Marmura MJ","year":"2012","unstructured":"Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol. 2012, 14:27-35. 10.1007\/s11940-011-0150-9","journal-title":"Curr Treat Options Neurol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199819050-00005","article-title":"Migraine in pregnancy: what are the safest treatment options?","volume":"19","author":"Pfaffenrath V","year":"1998","unstructured":"Pfaffenrath V, Rehm M. Migraine in pregnancy: what are the safest treatment options?. Drug Saf. 1998, 19:383-8. 10.2165\/00002018-199819050-00005","journal-title":"Drug Saf"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-019-0556-3","article-title":"Beta-blockers for migraine prevention: a review article","volume":"21","author":"Danesh A","year":"2019","unstructured":"Danesh A, Gottschalk PC. Beta-blockers for migraine prevention: a review article. Curr Treat Options Neurol. 2019, 21:20. 10.1007\/s11940-019-0556-3","journal-title":"Curr Treat Options Neurol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2010.505601","article-title":"Migraine therapy during pregnancy and lactation","volume":"9","author":"Cassina M","year":"2010","unstructured":"Cassina M, Di Gianantonio E, Toldo I, Battistella PA, Clementi M. Migraine therapy during pregnancy and lactation. Expert Opin Drug Saf. 2010, 9:937-48. 10.1517\/14740338.2010.505601","journal-title":"Expert Opin Drug Saf"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0338","article-title":"\u03b2-blocker use in pregnancy and the risk for congenital malformations: an international cohort study","volume":"169","author":"Bateman BT","year":"2018","unstructured":"Bateman BT, Heide-J\u00f8rgensen U, Einarsd\u00f3ttir K, et al.. \u03b2-blocker use in pregnancy and the risk for congenital malformations: an international cohort study. Ann Intern Med. 2018, 169:665-73. 10.7326\/M18-0338","journal-title":"Ann Intern Med"},{"key":"ref64","article-title":"Migraine in pregnancy","volume":"53","author":"Aub\u00e9 M","year":"1999","unstructured":"Aub\u00e9 M. Migraine in pregnancy. Neurology. 1999, 53:S26-8.","journal-title":"Neurology"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.7326\/L19-0157","article-title":"\u03b2-blocker use in pregnancy and the risk for congenital malformations","volume":"170","author":"Bateman BT","year":"2019","unstructured":"Bateman BT, Huybrechts KF, Hernandez-Diaz S, Kieler H, Zoega H. \u03b2-blocker use in pregnancy and the risk for congenital malformations. Ann Intern Med. 2019, 170:909-10. 10.7326\/L19-0157","journal-title":"Ann Intern Med"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-16-S1-A24","article-title":"Migraine in pregnancy","volume":"16","author":"Sacco S","year":"2015","unstructured":"Sacco S, Ripa P. Migraine in pregnancy. J Headache Pain. 2015, 16:A24. 10.1186\/1129-2377-16-S1-A24","journal-title":"J Headache Pain"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1111\/head.12540","article-title":"Pregnancy and lactation - migraine management","volume":"55","author":"Tepper D","year":"2015","unstructured":"Tepper D. Pregnancy and lactation - migraine management. Headache. 2015, 55:607-8. 10.1111\/head.12540","journal-title":"Headache"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.111006351.x","article-title":"Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan","volume":"41","author":"K\u00e4ll\u00e9n B","year":"2001","unstructured":"K\u00e4ll\u00e9n B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache. 2001, 41:351-6. 10.1046\/j.1526-4610.2001.111006351.x","journal-title":"Headache"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-2-573","article-title":"Preventive effect of cyproheptadine hydrochloride in refractory patients with frequent migraine","volume":"2","author":"Okuma H","year":"2013","unstructured":"Okuma H, Iijima K, Yasuda T, Tokuoka K, Kitagawa Y. Preventive effect of cyproheptadine hydrochloride in refractory patients with frequent migraine. SpringerPlus. 2013, 2:573. 10.1186\/2193-1801-2-573","journal-title":"SpringerPlus"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1986.tb02532.x","article-title":"Migraine treatment with calcium channel blockers","volume":"58","author":"Andersson KE","year":"1986","unstructured":"Andersson KE, Brandt L, Hindfelt B, Ryman T. Migraine treatment with calcium channel blockers. Acta Pharmacol Toxicol (Copenh). 1986, 58:161-7. 10.1111\/j.1600-0773.1986.tb02532.x","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199346060-00003","article-title":"New uses for calcium channel blockers. Therapeutic implications","volume":"46","author":"Fisher M","year":"1993","unstructured":"Fisher M, Grotta J. New uses for calcium channel blockers. Therapeutic implications. Drugs. 1993, 46:961-75. 10.2165\/00003495-199346060-00003","journal-title":"Drugs"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13320","article-title":"Efficacy and feasibility of antidepressants for the prevention of migraine in adults: a meta-analysis","volume":"24","author":"Xu XM","year":"2017","unstructured":"Xu XM, Yang C, Liu Y, Dong MX, Zou DZ, Wei YD. Efficacy and feasibility of antidepressants for the prevention of migraine in adults: a meta-analysis. Eur J Neurol. 2017, 24:1022-31. 10.1111\/ene.13320","journal-title":"Eur J Neurol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002919.pub2","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches","author":"Moja PL","year":"2005","unstructured":"Moja PL, Cusi C, Sterzi RR, Canepari C. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev. 2005, CD002919. 10.1002\/14651858.CD002919.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08111703","article-title":"Parsing risk for the use of selective serotonin reuptake inhibitors in pregnancy","volume":"166","author":"Yonkers KA","year":"2009","unstructured":"Yonkers KA. Parsing risk for the use of selective serotonin reuptake inhibitors in pregnancy. Am J Psychiatry. 2009, 166:268-70. 10.1176\/appi.ajp.2008.08111703","journal-title":"Am J Psychiatry"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002919.pub3","article-title":"Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults","volume":"4","author":"Banzi R","year":"2015","unstructured":"Banzi R, Cusi C, Randazzo C, Sterzi R, Tedesco D, Moja L. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. Cochrane Database Syst Rev. 2015, 4:CD002919. 10.1002\/14651858.CD002919.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-818902-3.00014-2","article-title":"Antidepressants in pregnancy","author":"Komorowski J","year":"2022","unstructured":"Komorowski J. Antidepressants in pregnancy. Clinical Pharmacology During Pregnancy. Elsevier, 2022. 311-21. 10.1016\/B978-0-12-818902-3.00014-2"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.54270","article-title":"Indian consensus on the role of amitriptyline in migraine prophylaxis","volume":"16","author":"Singh S","year":"2024","unstructured":"Singh S, Srinivasan AV, Banerjee TK, Patel KN, Muchhala SS, Kotak BP. Indian consensus on the role of amitriptyline in migraine prophylaxis. Cureus. 2024, 16:e54270. 10.7759\/cureus.54270","journal-title":"Cureus"},{"key":"ref78","article-title":"Canadian Headache Society guideline for migraine prophylaxis","volume":"39","author":"Pringsheim T","year":"2012","unstructured":"Pringsheim T, Davenport W, Mackie G, et al.. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012, 39:S1-59.","journal-title":"Can J Neurol Sci"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003322","article-title":"Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset","volume":"17","author":"Patorno E","year":"2020","unstructured":"Patorno E, Hernandez-Diaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H, Bateman BT. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLoS Med. 2020, 17:e1003322. 10.1371\/journal.pmed.1003322","journal-title":"PLoS Med"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001065","article-title":"Gabapentin use during pregnancy and lactation with and without concurrent opioid exposure: considerations and future directions","volume":"17","author":"DeLisle A","year":"2023","unstructured":"DeLisle A, Jones HE, Jansson LM. Gabapentin use during pregnancy and lactation with and without concurrent opioid exposure: considerations and future directions. J Addict Med. 2023, 17:123-5. 10.1097\/ADM.0000000000001065","journal-title":"J Addict Med"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828f18c1","article-title":"Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study","volume":"23","author":"Fujii H","year":"2013","unstructured":"Fujii H, Goel A, Bernard N, et al.. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology. 2013, 23:1565-70. 10.1212\/WNL.0b013e31828f18c1","journal-title":"Neurology"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010609","article-title":"Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults","volume":"2013","author":"Linde M","year":"2013","unstructured":"Linde M, Mulleners WM, Chronicle EP, McCrory DC. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013, 2013:CD010609. 10.1002\/14651858.CD010609","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/297823-abortive-and-prophylactic-therapies-to-treat-migraine-in-pregnancy-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T07:56:00Z","timestamp":1728028560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/297823-abortive-and-prophylactic-therapies-to-treat-migraine-in-pregnancy-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":82,"URL":"https:\/\/doi.org\/10.7759\/cureus.70807","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,4]]}}}